Skip to main content
. 2022 Sep 28;13:1026509. doi: 10.3389/fimmu.2022.1026509

Table 1.

Clinical characteristics of subjects.

Parameter (Unit) PDM-TC (N = 19) PDM-C (N = 19) NG (N = 10)
Before After Before After Before After
Wt (kg) 61.58 ± 9.42 59.21 ± 9.05b 65.49 ± 11.08 65.37 ± 11.05 60.45 ± 7.17 60.38 ± 8.27
BMI (kg/m2) 24.99 ± 3.64 24.15 ± 3.42b 25.41 ± 2.57 25.34 ± 2.38 23.89 ± 1.80 23.83 ± 1.97
SBP (mmHg) 143.05 ± 19.80 124.79 ± 14.56b 138.16 ± 18.37 136.53 ± 19.66 128.20 ± 14.73 126.90 ± 16.70
DBP (mmHg) 80.84 ± 8.20 74.00 ± 10.01bd 84.32 ± 7.82 82.27 ± 7.04 84.80 ± 13.61 83.10 ± 10.50
WHR 0.91 ± 0.05 0.89 ± 0.04d 0.91 ± 0.05 0.96 ± 0.04 0.89 ± 0.06 0.91 ± 0.06
FBG (mmol/L) 6.39 ± 0.31d 6.04 ± 0.31bd 6.40 ± 0.31 6.60 ± 0.34 5.42 ± 0.42 5.44 ± 0.30
2 hPG (mmol/L) 9.17 ± 2.17d 7.56 ± 2.47bc 8.62 ± 0.77 8.66 ± 0.72 6.70 ± 0.73 6.94 ± 0.72
CRP (mg/dl) 1.94 ± 0.11c 1.86 ± 0.11bd 2.06 ± 0.15 2.09 ± 0.13 1.95 ± 0.12 1.92 ± 0.11
HbA1C (%) 6.23 ± 0.33d 6.00 ± 0.34bd 6.24 ± 0.29 6.32 ± 0.50 5.60 ± 0.28 5.65 ± 0.18
HbA1 (%) 7.65 ± 0.53d 7.39 ± 0.44bd 7.65 ± 0.39 7.56 ± 0.65 6.64 ± 0.44 6.62 ± 0.36
FINs (μU/mL) 12.22 ± 5.97c 9.73 ± 4.72bc 13.98 ± 5.23 13.08 ± 4.62 8.76 ± 2.84 9.54 ± 3.28
HOMA-IR 3.13 ± 1.71d 2.27 ± 1.15bd 3.74 ± 1.41 3.66 ± 1.35 1.92 ± 0.73 2.04 ± 0.81
TG (mmol/L) 1.65 ± 0.83 1.56 ± 0.86 2.00 ± 0.87 2.19 ± 0.95 1.44 ± 1.07 1.68 ± 0.73
TC (mmol/L) 5.58 ± 1.05 5.33 ± 1.05b 5.03 ± 1.01 5.06 ± 0.92 5.17 ± 1.05 5.16 ± 0.78
HDL-C (mmol/L) 1.41 ± 0.34 1.41 ± 0.33 1.58 ± 0.52 1.65 ± 0.63 1.37 ± 0.32 1.34 ± 0.28
LDL-C (mmol/L) 3.32 ± 0.84 3.11 ± 0.88b 3.42 ± 0.72 3.44 ± 0.73 3.15 ± 0.67 3.17 ± 0.49

Comparison in the group,aP < 0.05, bP < 0.01; Comparison between groups, cP < 0.05, dP < 0.01. Wt, weight; BMI, body mass index; WHR, waist-to-hip ratio; FBG, fasting blood glucose; 2 h PG, 2 hours plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; CRP, C-reactive protein; HbA1c, haemoglobinA1c; HbA1, total glycosylated hemoglobin; FINs, fasting insulin; HOMA-IR, homeostatic model assessment for insulin resistance.